Abstract P3-12-01: 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitors (AIs) in the adjuvant setting. A phase II prospective, randomized, double-blind placebo-controlled study - “the Blissafe study”
Abstract:BACKGROUND: 0.005% Estriol vaginal gel is a new formulation for the local treatment of postmenopausal vaginal atrophy which delivers an ultra-low dose of estriol (50mcg) per application. A study is proposed with the hypothesis that 0.005% Estriol vaginal gel is an efficacious and safe option to treat moderate to severe symptoms of vaginal atrophy caused by AIs without producing significant decline in gonadotropins or increase in systemic estrogens.
METHODS: 70 women with breast cancer receiving … Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.